FIELD: medicine.
SUBSTANCE: invention relates to methods of treating, preventing, and controlling metabolic disorders and reducing cardiovascular risk. Methods envisage administering to a subject in need thereof a fusion protein Fc and a variant protein of fibroblast growth factor 21 (FGF21) containing the amino acid sequence SEQ ID NO: 11, in dose of 300 mg every 4 weeks, subcutaneously.
EFFECT: inventions make it possible to reduce content of fat in liver, high level of LDL cholesterol, total cholesterol and triglycerides in a subject and reduce cardiovascular risk.
17 cl, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE | 2020 |
|
RU2804335C2 |
| PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS, LIVER FIBROSIS AND LIVER CIRRHOSIS, INCLUDING FUSION PROTEINS | 2017 |
|
RU2795548C2 |
| FGF21 MIMETIC ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2774368C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING PEPTIDE VERSIONS, AND METHODS OF USING THEM | 2015 |
|
RU2729161C2 |
| PROTEINS WITH A DOUBLE FUNCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2741345C2 |
| FGF21 FUSED WITH LONG-ACTING PROTEINS AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2016 |
|
RU2741087C2 |
| METHODS FOR TREATING FGF21-RELATED DISORDERS | 2016 |
|
RU2752530C2 |
| METHODS OF TREATING TISSUE CALCIFICATION | 2015 |
|
RU2770698C2 |
| POLYVALENT MODULATORS OF REGULATORY T-CELLS | 2017 |
|
RU2769871C2 |
| POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION | 2017 |
|
RU2751483C2 |
